Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

A case study of single-pill combination therapy: the ezetimibe/simvastatin combination for treatment of hyperlipidemia.

Huang X, Chen DY.

ChemMedChem. 2012 Nov;7(11):1882-94. doi: 10.1002/cmdc.201200287. Epub 2012 Aug 20. Review.

PMID:
22907901
2.

Lipid-lowering effects of ezetimibe and simvastatin in combination.

Ijioma N, Robinson JG.

Expert Rev Cardiovasc Ther. 2011 Feb;9(2):131-45. doi: 10.1586/erc.10.179. Review.

PMID:
21453210
3.

Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.

Moon YS, Chun P, Chung S.

Drugs Today (Barc). 2007 Jan;43(1):35-45. Review.

PMID:
17315051
4.

Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia.

Murdoch D, Scott LJ.

Am J Cardiovasc Drugs. 2004;4(6):405-22. Review.

PMID:
15554726
5.

Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.

Kastelein JJ, Sankatsing RR.

Int J Clin Pract. 2005 Dec;59(12):1464-71. Review.

PMID:
16351680
6.

In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease.

[No authors listed]

Med Lett Drugs Ther. 2012 Jan 9;54(1381):4. No abstract available.

PMID:
22233589
7.
8.

Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.

Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF.

J Clin Pharm Ther. 2009 Jun;34(3):267-76.

PMID:
19650249
9.

Ezetimibe + simvastatin (Merck/Schering-Plough).

Flores NA.

Curr Opin Investig Drugs. 2004 Sep;5(9):984-92. Review.

PMID:
15503655
10.

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T.

Am J Cardiol. 2006 Jan 15;97(2):223-8. Epub 2005 Nov 21.

PMID:
16442367
11.

Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct.

Mitka M.

JAMA. 2008 Feb 27;299(8):885-7. doi: 10.1001/jama.299.8.885. No abstract available.

PMID:
18314425
12.

Ezetimibe and recent clinical trials: a look on the bright side.

Ahmed MH.

Expert Opin Drug Saf. 2010 Jul;9(4):511-4. doi: 10.1517/14740331003702376.

PMID:
20377476
13.

Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.

Farnier M.

Fundam Clin Pharmacol. 2007 Nov;21 Suppl 2:27-8. Review.

PMID:
18001317
14.

Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipidemia in peritoneal dialysis patients.

Suzuki H, Inoue T, Watanabe Y, Kikuta T, Sato T, Tsuda M.

Adv Perit Dial. 2010;26:53-7.

PMID:
21348380
15.
16.

The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome.

Miller M, DiNicolantonio JJ, Can M, Grice R, Damoulakis A, Serebruany VL.

Cardiology. 2013;125(2):74-7. doi: 10.1159/000347134. Epub 2013 May 7.

PMID:
23652826
17.

Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.

Agouridis AP, Filippatos TD, Tsimihodimos V, Elisaf MS.

Expert Rev Cardiovasc Ther. 2011 Mar;9(3):355-66. doi: 10.1586/erc.11.4. Review.

PMID:
21438815
18.

Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy.

Zinellu A, Sotgia S, Loriga G, Deiana L, Satta AE, Carru C.

Amino Acids. 2012 Oct;43(4):1499-507. Epub 2012 Jan 26.

PMID:
22278741
19.

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.

Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.

Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.

PMID:
20152243
20.

Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults.

Lee YH, Kim MJ, Choi CI, Bae JW, Jang CG, Lee SY.

Arch Pharm Res. 2011 Aug;34(8):1331-7. doi: 10.1007/s12272-011-0813-9. Epub 2011 Sep 11.

PMID:
21910055

Supplemental Content

Support Center